News
ACTU ▲ +5.9% - Actuate Therapeutics, Inc. Common stock
ACTU ▲ +5.9% - Actuate Therapeutics, Inc. Common stock
$ACTU - Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
04-NOV-2026 08:00 AM ET
Share this post
More filings for $ACTU
ACTU ▲ +11.8% - Actuate Therapeutics, Inc. Common stockNov 2, 2026ACTU - Actuate Therapeutics, Inc. Common stock - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 30, 2026ACTU ▼ -27.5% - Actuate Therapeutics, Inc. Common stockOct 27, 2026ACTU ▼ -8.8% - Actuate Therapeutics, Inc. Common stockSep 9, 2026ACTU ▼ -0.7% - Actuate Therapeutics, Inc. Common stockSep 9, 2026
View full $ACTU filing history →💬 Comments
Loading comments…
Leave a comment